EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY-SA 4.0

FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN EFEK SAMPING TERAPI EGFR-TKI PADA PASIEN KANKER PARU NON-SEL KECIL: SCOPING REVIEW

Rahmawati Azara Putri, Eca Enjiska, Mally Ghinan Sholih

JHN: Journal of Health and Nursing · 19.11.2026 · 4 (2) · 757-775

DOI: 10.58738/jhn.v4i2.2016 ↗

Kurz gefasst

Scoping Review in der Zeitschrift JHN: Journal of Health and Nursing, online erschienen am 19.11.2026. Verfasst von Rahmawati Azara Putri und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard therapy for EGFR-mutated non-small cell lung cancer (NSCLC), yet adverse events vary across patients. This scoping review aimed to map the associated factors related to the occurrence and Common Terminology Criteria for Adverse Events (CTCAE) grade of EGFR-TKI adverse events in NSCLC patients and to describe the biological and pharmacological mechanisms that may explain these associations. Following PRISMA-ScR and Joanna Briggs Institute (JBI) guidance with the Population, Concept, Context (PCC) framework, searches across PubMed, Scopus, and Web of Science (2016–2026) identified 412 records. After removing 118 duplicates, 294 records underwent independent dual screening, 68 full texts were assessed, and 14 primary studies were included and appraised using JBI checklists. Four categories of associated factors emerged. First, ABCB1 (1236C>T, 2677G>T/A), ABCG2 (421C>A), and CYP2D6 polymorphisms were associated with slower drug clearance (erlotinib CL/F reduced by 29.4%), diarrhea (87.5% vs. 36.4%; p = 0.002), CTCAE grade 2–3 rash, and hepatic dysfunction. Second, baseline serum albumin ≤ 3.0 g/dL was independently associated with CTCAE grade 4–5 interstitial lung disease (ILD) (aOR = 3.91; 95% CI 1.20–12.71), presumably via a hypothesized increase in unbound drug fraction, whereas body weight < 40 kg was associated with CTCAE grade ≥ 3 diarrhea (aOR = 7.93; 95% CI 2.32–27.10). Third, a 30 mg vs. 40 mg/day afatinib starting dose was associated with fewer CTCAE grade 3 adverse events (7% vs. 24%; p < 0.0001), and dose reduction lowered diarrhea, rash, and paronychia severity without compromising progression-free survival (HR = 0.86; 95% CI 0.58–1.29). Fourth, older age (≥ 60–65 years; aOR = 2.32), female sex (aOR = 2.04), BMI ≥ 25 kg/m² on gefitinib (aOR = 4.571), and concomitant medications/polypharmacy were associated with organ toxicities. In conclusion, pre-treatment risk evaluation, CTCAE grade monitoring, and dose reduction may be considered in accordance with official guidelines and product labeling, as the mapped evidence is predominantly observational and associative.

Zitieren

APA

Putri, R. A., Enjiska, E., & Sholih, M. G. (2026). FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN EFEK SAMPING TERAPI EGFR-TKI PADA PASIEN KANKER PARU NON-SEL KECIL: SCOPING REVIEW. JHN: Journal of Health and Nursing, 4(2), 757-775. https://doi.org/10.58738/jhn.v4i2.2016

Vancouver

Putri RA, Enjiska E, Sholih MG. FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN EFEK SAMPING TERAPI EGFR-TKI PADA PASIEN KANKER PARU NON-SEL KECIL: SCOPING REVIEW. JHN: Journal of Health and Nursing. 2026;4(2):757-775. doi:10.58738/jhn.v4i2.2016

BibTeX
@article{Putri2026,
  author = {Putri, Rahmawati Azara and Enjiska, Eca and Sholih, Mally Ghinan},
  title = {FAKTOR YANG BERHUBUNGAN DENGAN KEJADIAN EFEK SAMPING TERAPI EGFR-TKI PADA PASIEN KANKER PARU NON-SEL KECIL: SCOPING REVIEW},
  journal = {JHN: Journal of Health and Nursing},
  year = {2026},
  volume = {4},
  number = {2},
  pages = {757--775},
  doi = {10.58738/jhn.v4i2.2016}
}
Kostenlos starten →